CatapultRx: Medicines Manufacturing Start and Scale; Supporting SMEs to start, scale, and succeed
The CatapultRx programme is a targeted initiative designed to accelerate the growth of high-potential SMEs in the Medicines Manufacturing sector.
The programme aims to support the development, delivery or manufacture of medicines, including but not limited to small molecules, biopharmaceuticals, cell and gene therapies and biologics.
Its primary aim is to fast-track the technical development and commercial readiness of SMEs by providing technical access to the world-class expertise, facilities, and networks of CPI, Cell and Gene Therapy Catapult (CGTC), and Medicines Discovery Catapult (MDC).
The programme’s objectives are to:
- Help SMEs overcome critical technical barriers in their development journey.
- Strengthen SME positioning for follow-on investment, strategic partnerships, and market growth.
CatapultRx offers SMEs indirect financial support valued up to £90,000, under the Minimal Financial Assistance (MFA), by funding the Catapult partner to deliver specific, lab-based projects.
This funding is from Innovate UK, Transforming Medicines Manufacturing Programme.
You can download the programme brochure here:
Applications are open at 9:00 on Monday, 12 January, 2026 and will close at 9:00 on Monday, 19 January, 2026.